Eidos Therapeutics, Inc.
EIDOS THERAPEUTICS (EIDX) SHAREHOLDER ALERT - Andrews & Springer LLC Is Seeking More Cash for Shareholders of Eidos Therapeutics, Inc.
(Wilmington, DE) Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential breach of fiduciary duty claims against the Board of Directors of Eidos Therapeutics, Inc. (NASDAQ: EIDX) (“Eidos” or the “Company”) relating to the sale of the Company to BridgeBio Pharma, Inc. (“BridgeBio”), which owns and controls over 63% of Eidos. The two parties have announced that they reached an agreement in principle pursuant to which BridgeBio will acquire Eidos. As a result of the merger, Eidos shareholders are only anticipated to receive either 1.85 shares of BridgeBio common stock or $73.26 per share in cash in exchange for each share of Eidos.
Andrews & Springer’s investigation so far has revealed that the consideration Eidos shareholders are expected to receive is inadequate. Our Firm's investigation so far has discovered that the process leading up to the announcement of the merger appears to have significant conflicts of interest, thus making the process and consideration unfair. Andrews & Springer is also investigating whether the Eidos directors breached their fiduciary duties by failing to adequately shop the company and maximize shareholder value.
If you own shares of Eidos and want to receive additional information and protect your investments free of charge, please visit us at http://www.andrewsspringer.com/cases-investigations/eidos-merger-class-action-investigation/ or contact Craig J. Springer, Esq. at cspringer@andrewsspringer.com, or call toll free at 1-800-423-6013. You may also follow us on LinkedIn – www.linkedin.com/company/andrews-&-springer-llc, Twitter – www.twitter.com/AndrewsSpringer or Facebook - www.facebook.com/AndrewsSpringer for future updates.